Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04725799 · ClinicalTrials.gov registry record
Additional Signals for Exercise, Stress and Sleep and Prediction of Glucose Levels for AP Systems
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 23
- Enrollment target
NCT04725799: Completed study, sponsored by University of Illinois at Chicago.
NCT04725799 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04725799 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The objective of this research is to determine the most informative variables for detecting exercise, acute stress and sleep, identify select sensors that report these variables, and develop the algorithms to detect the occurrence of exercise, stress and sleep, to discriminate them and to determine their characteristics. Research is needed to identify which wearable devices report the most informative and predictive variables of exercise, acute stress and sleep with desired precision and accuracy, determine the best location to wear them for collecting reliable and informative data, and to distill accurate knowledge from data reported by wearable sensors. Data and their interpretation should be informative for various types of physical activities, stages of sleep, and types and intensities of acute stress, and concurrent occurrence of these factors. The investigators will use several devices (chest band, wristband and skin patches) to collect data and evaluate their information content and contribution to improvement of glucose concentration prediction, best locations for collecting accurate and reliable information by conducting clinical and free-living experiments at-home to assess the contributions of the wearable device in improving the accuracy of glucose concentration prediction and the performance of the multivariable artificial pancreas.
Primary Outcome
• Glucose concentration (mg/dl) will be measured by: Continuous Glucose Monitor (DEXCOM \[US G5 PLATINUM/G6\]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-05-24 |
| Est. Completion | 2021-07-13 |
What the finished NCT04725799 record still lists
NCT04725799 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04725799 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04725799 about?
NCT04725799 is a clinical study titled "Additional Signals for Exercise, Stress and Sleep and Prediction of Glucose Levels for AP Systems". The objective of this research is to determine the most informative variables for detecting exercise, acute stress and sleep, identify select sensors that report these variables, and develop the algorithms to detect the occurrence of exercise, stress and sleep, to discriminate them and to determine ...
What is the current status of trial NCT04725799?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2018-05-24. Estimated completion is 2021-07-13.
Who is sponsoring clinical trial NCT04725799?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI